Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil;Erste ergebnisse der therapie der psoriasisarthritis mit mycophenolatmofetil

Zeitschrift fur Rheumatologie

Volumn 61, Issue 5, 2002, Pages 545-550

  Schrader P ^a   Mooser, G ^b   Peter, R U ^b   Puhl, W ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Rehabilitationskrankenhaus Ulm gGmbH   (Germany)

Author keywords

Mycophenolate mofetil; Pilot study; Psoriatic arthritis

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; JOINT FUNCTION; LEUKOCYTE COUNT; MALE; MEDICAL ASSESSMENT; PAIN; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; ARTHRITIS, PSORIATIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PAIN MEASUREMENT; PILOT PROJECTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036924819     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-002-0369-7     Document Type: Article

References (34)

1. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT (1995) Longterm methotrexat therapy in psoriatic arthritis: Clinical and radiological outcome. J Rheumatol 22:241-245
2. Arnett FC (1987) Seronegative Spondylarthropathies. Bull Rheum Dis 37:1-12
3. Arnett FC, Reveille JD, Duvic M (1991) Psoriasis and psoriatic arthritis associated with human immune deficiency virus infection. Rheum Dis Clin North Am 17:59-78
4. Bullinger M, Kirchberger I, Ware J (1995) Der deutsche SF-36 Health Survey. Übersetzung und psychometrische testung eines krankheitsüber-greifenden instruments zur erfassung der gesundheitsbezogenen lebensqualität. Z Gesundheitswiss 3:21-36
5. Bullingham RES, Andrew JN, Kamm BR (1998) Clinical pharmacokinetics of Mycophenolate mofetil. Clin Pharmacokinet 34 (6):429-455
6. Cuéllar ML, Silveira LH, Espinoza LR (1994) Recent developments in psoriatic arthritis. Curr Opin Rheumatol 6:378-384
7. Cuellar ML, Espinoza LR (1996) Management of spondylarthropathies: Curr Opin Rheumatol 8:288-295
8. Eibschutz B, Baird SM, Weisman MH, Amox DG, Spellman M, Piacquadio D, Carrera CJ, Carson DA (1995) Oral 2 chlorodeoxyadenosine in psoriatic arthritis: A preliminary report. Arthritis Rheum 38:1604-1609
9. Finzi AF, Gibelli E (1991) Psoriatic arthritis. Int J Dermatol 30:1-7
10. FitzGerald O, Kane D (1997) Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis. Cur Op Rheumatol 9:295-301
11. Fournié B, Granel J, Heraud A, Cambon Thomsen A, Pages M, Drome C, Ohayon E, Fournié A (1991) HLA-B et rhumatisme psoriatique. Rev Rhum Mal Osteoartic 58:269-273
12. Glicklich D, Acharya A (1998) Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 32(2):318-322
13. Goldblum R (1993) Therapy of rheumatoid arthritis with Mycophenolate mofetil. Clin Exp Rheumatol 11:5117-5119
14. Gomez-Vaquero C, Rodriguez-Moreno J, Ros S, Marcos R, Fiter J, Roig-Escofet D (1996) Termination of Disease-modifying Drugs in Psoriatic Arthritis 35:564-567
15. Gran JT, Bomer E (1996) Acute sarcoid arthritis: A favourable outcome? A retrospective survey of 49 patients with review of the literature. Scand J Rheumatol 25:70-73
16. Haufs MG, Beissert S, Grabbe S (1998) Psoriasis vulgaris treated successfully with Mycophenolate mofetil. Br J Dermatol 138:179-181
17. Helliwell P, Marchesoni A, Peters M, Barker M, Wright V (1991) A reevaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 30:339-345
18. Huckins D, Felson DT, Holick M (1990) Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: A pilot study. Arthritis Rheum 33(11):1723-1727
19. Jones G, Crotty M, Brooks P (1997) Psoriatic arthritis: A quantitative overview of therapeutic options. Br J Rheumatol 36:95-99
20. Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348:1357-1359
21. Molin L (1973) Psoriasis. Acta Derm Venerol (Stockh) Suppl 72:123-128
22. Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55-78
23. Peter RU, Ruzicka T, Donhauser G, Braun-Falco O (1992) Acrodermatitis continuatype of pustular psoriasis responds to low-dose cyclosporine. J Amer Acad Dermatol 23:515-516
24. Peter RU, Ruzicka T (1992) Cyclosporin A in der Therapie entzündlicher Dermatosen. Hautarzt 43:687-694
25. Rakhmatov AB, Chichenina IV, Dizik LI, Bodrova NN (1990) The genetic markers of psoriasis. Vestn Dermatol Venerol 5:40-43
26. Rappersburger K, Meingasser JG, Fialla R, Fodinger D, Sterniczy B, Rauch S, Putz E, Stutz A, Wolff K (1996) Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 106:701-710
27. Ruzicka T (1996) Psoriatic arthritis. Arch Dermatol 132:215-219
28. Scarpa R, Biondi Oriente C, Oriente P (1997) The classification of psoriatic arthritis: What will happen in the future? J Am Acad Dermatol 35:78-83
29. Sievers TM, Rossi SJ, Ghobrial RM, Nishimura P, Kawano M, Holt CD (1997) Mycophenolate mofetil. Pharmacotherapy 17(6):1178-1197
30. Silverman Kitchin EJ, Keltz Pomeranz M, Pak G (1997) Rediscovering mycophenolic acid: A review of ist mechanism, side effects, and potential uses. J Am Acad Dermatol 37:445-449
31. Stern RS (1987) The epidemiology of cutaneus diseases. In: Fitzpatrick TB (Hrsg) Dermatology in General Medicine. McGraw, Hill International Book Co, New York
32. Veys EM, Mielants H (1994) Current concepts in psoriatic arthritis. Dermatology 189(Suppl 2):35-41
33. Ware JE, Snow KK, Kosinski M, Gandek B (1993) SF-36 health survey. Manual and Interpretation Guide. Nisural Press, Boston
34. Wright V (1987) Skin and arthritis. Clin Exp Rheumatol 5(Suppl 1):75-97